Antifungal Agents Spectrum of Activity, Pharmacology, and Clinical Indications

被引:251
作者
Nett, Jeniel E. [1 ,2 ]
Andes, David R. [1 ,2 ]
机构
[1] Univ Wisconsin, Dept Med, Madison, WI 53705 USA
[2] Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53705 USA
关键词
Antifungal; Spectrum of activity; Azole; Echinocandins; Amphotericin B; Pharmacokinetics; Indications; Toxicity; IN-VITRO ACTIVITIES; INFECTIOUS-DISEASES-SOCIETY; LIPOSOMAL AMPHOTERICIN-B; ITRACONAZOLE ORAL SOLUTION; INVASIVE FUNGAL-INFECTIONS; MURINE CANDIDIASIS MODEL; CENTRAL-NERVOUS-SYSTEM; AZOLE-REFRACTORY OROPHARYNGEAL; RANDOMIZED-CONTROLLED-TRIALS; CELL TRANSPLANT RECIPIENTS;
D O I
10.1016/j.idc.2015.10.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The currently available antifungal therapies vary significantly in terms of spectrum of activity, pharmacologic properties, toxicity, and potential for drug-drug interactions. This article provides a history of antifungal development and discusses the characteristics of individual drugs and drug classes, including the amphotericin B formulations, the triazoles, the echinocandins, and flucytosine. For each drug, the clinically relevant pharmacokinetics are reviewed, the spectrum of activity described, and the Food and Drug Administration-approved clinical indications examined. Anti fungal side-effects, therapeutic drug monitoring, and drug-drug interactions are summarized. The variations among different formulations are highlighted.
引用
收藏
页码:51 / +
页数:34
相关论文
共 230 条
  • [1] Systemic antifungal agents - Drug interactions of clinical significance
    Albengres, E
    Le Louet, H
    Tillement, JP
    [J]. DRUG SAFETY, 1998, 18 (02) : 83 - 97
  • [2] Omeprazole Significantly Reduces Posaconazole Serum Trough Level
    Alffenaar, Jan-Willem C.
    van Assen, Sander
    van der Werf, Tjip S.
    Kosterink, Jos G. W.
    Uges, Donald R. A.
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 48 (06) : 839 - 839
  • [3] High voriconazole trough levels in relation to hepatic function: how to adjust the dosage?
    Alffenaar, Jan-Willem C.
    de Vos, Tessa
    Uges, Donald R. A.
    Daenen, Simon M. G. J.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (02) : 262 - 263
  • [4] Refractory aspergillus pneumonia in patients with acute leukemia - Successful therapy with combination caspofungin and liposomal amphotericin
    Aliff, TB
    Maslak, PG
    Jurcic, JG
    Heaney, ML
    Cathcart, KN
    Sepkowitz, KA
    Weiss, MA
    [J]. CANCER, 2003, 97 (04) : 1025 - 1032
  • [5] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
    Ally, R
    Schürmann, D
    Kreisel, W
    Carosi, G
    Aguirrebengoa, K
    Dupont, B
    Hodges, M
    Troke, P
    Romero, AJ
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) : 1447 - 1454
  • [6] In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents
    Almyroudis, Nikolaos G.
    Sutton, Deanna A.
    Fothergill, Annette W.
    Rinaldi, Michael G.
    Kusne, Shimon
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (07) : 2587 - 2590
  • [7] In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods
    Alvarado-Ramirez, Eidi
    Torres-Rodriguez, Josep M.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (07) : 2420 - 2423
  • [8] Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature
    Anaissie, EJ
    Darouiche, RO
    AbiSaid, D
    Uzun, O
    Mera, J
    Gentry, LO
    Williams, T
    Kontoyiannis, DP
    Karl, CL
    Bodey, GP
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (05) : 964 - 972
  • [9] Making sense of posaconazole therapeutic drug monitoring: a practical approach
    Ananda-Rajah, Michelle R.
    Grigg, Andrew
    Slavin, Monica A.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2012, 25 (06) : 605 - 611
  • [10] In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
    Andes, D.
    Diekema, D. J.
    Pfaller, M. A.
    Prince, R. A.
    Marchillo, K.
    Ashbeck, J.
    Hou, J.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (02) : 539 - 550